İsmail APAK, Yusuf TAMAM, Gönül ÇAKMAK, Banu TAMAM, Veysi TABAK

Uzun süreli karbamazepin monoterapisinin epilepsi hastalarında serum lipit düzeylerine etkisi

Bu çalışmada antiepileptik olarak tek başına uzun süreli karbamazepin kullanan epilepsi hastalarında karbamazepinin kan serum lipit düzeylerine olan etkisinin araştırılması amaçlanmıştır. Çalışma grubu epilepsi tanısı alan ve bu nedenle en az bir yıldır karbamazepin kullanan 10'u kadın, 20'si erkek 30 hastadan, kontrol grubu ise yaş ve cinsiyet olarak uyumlu 30 sağlıklı denekten oluşmuştur. Tüm deneklerin serum kolesterol (total kolesterol, HDL, LDL ) ve trigliserit düzeyleri ve LDL/HDL oranları belirlenmiştir. Çalışma grubunun serum HDL kolesterol, trigliserit düzeyleri kontrol grubuna göre istatistiksel olarak anlamlı düzeyde yüksek, serum LDL kolesterol düzeyi ve LDL/HDL oranlarının kontrol grubuna göre anlamlı düzeyde düşüktü. Total kolesterol düzeylerinin ortalaması çalışma grubunda kontrol grubuna göre daha düşük olmasına karşın, bu farklılık istatistiksel olarak anlamlı değildi. Uzun süreli karbamazepin kullanımının kolesterol düzeylerine olan etkisi nedeniyle ateroskleroz ve koroner kalp hastalığının gelişme riskini azaltmaya katkıda bulunabileceği düşünülmüştür. Yapılacak uzun süreli ileriye dönük izlem çalışmaları bu konunun kesin biçimde aydınlatılmasına yardımcı olacaktır

The effect of long-term carbamazepine monotherapy on serum lipid levels in epilepsy patients

The aim of this study was to determine the effect of carbamazepine on serum lipid levels in epileptic patients who were on long-term carbamazepine monotherapy. The study group were comprised of 30 epileptic patients (10 female, 20 male) who have been on carbamazepine monotherapy for at least one year whereas control group consisted of 30 age and sex matched healthy controls. Serum cholesterol (total cholesterol, HDL cholesterol, LDL cholesterol) and triglyceride levels were measured and LDL/HDL ratio was calculated in all subjects. Serum HDL cholesterol and triglyceride levels of study group were significantly higher than control group whereas serum LDL cholesterol levels and LDL/HDL ratios of study group were lower than control group. Mean total cholesterol level of study group was lower than control group, however the difference did not reach statistical significance level. Because of its effect on cholesterol levels, long term carbamazepine could possibly have a positive influence in decreasing the risk of developing aterosclerosis and coronary heart disease. Long term prospective follow-up studies would be helpful to us in enlightening this issue definitely.

PDF

___

1. Mac TL, Tran DS, Quet F et al. Epidemiology,aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. 2007;6:533-543.
2. Muuronen A, Kaste M, Nikkila EA et al. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J (Clin Res Ed). 1985; 291:1481
3. Barth JD, Antzenius AC. Progression and regression of atherosclerosis, what roles for LDL-cholesterol and HDL-cholesterol: A prospective study. Eur Heart J. 1991; 12:952-957.
4. Berlit P, Krause KH, Heuck CC et al. Serum lipids and anticonvulsants.Acta Neurol Scand. 1982;66:328-334.
5. Isojarvi JI, Pakarinen AJ, Myllyla VV. Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol. 1993; 50:590-593.
6. Calandre EP, Rodriquez-Lopez C, Blazquez A et al. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand. 1991;83:250-253.
7. Sudhop T, Bauer J, Elger CE et al. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia. 1999;40:480-484.
8. Zeitlhofer J, Doppelbauer A, Tribl G et al.. Changes of serum lipid patterns during long-term anticonvulsive treatment. Clin Investig.1993; 71:574-578.
9. O’Neill B, Callaghan N, Stampleton M et al. Serum elevation of high density lipoprotein (HDL) cholesterol in epileptik patients taking carbamazepin or phenytoin. Acta Neurol Scand. 1982; 65;104-109.
10. Eiris J, Novo-Rodriguez MI, Del Rio M et al. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2000;41:1-7.
11. Bramswig S, Kerksiek A, Sudhop T, et al. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol. 2002; 282: 704-716.
12. Brown DW, Ketter TA, Crumlish J et al. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol. 1992;12:431-437.
13. Sozuer DT, Atakil D, Dogu O et al. Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr. 1997;156:565-567.
14. Fichsel H, Knüpfle G. Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia,. 1978; 19:323-336.
15. Dastur DK, Dave UP. Effect of prolonged anticonvulsant medication in epileptic patients: Serum lipids, B6, B12, and folic acid, proteins, and fine structure of liver. Epilepsia. 1987; 28: 147-159.
16. Nestler JE, Barlascini CO, Clore JN et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal man. J Clin Endocrinol Metab.1988; 66: 57-61.
17. lsojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol. 1989; 46: 1175-1178.
18. Isojarvi JI, Pakarinen AJ, Myllyla VV. A prospective study serum sex hormones during carbamazepine therapy. Epilepsy Res. 1991; 9; 139-144.
19. Luoma PV, Sotanıemı EA, Arranto AJ. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest. 1983; 43:671-675.
20. Levy RH, Pitlick H, Troupin AS et al. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther. 1975; 17:657-668.
21. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit. 2004;10: 50-52.
22. Calandre EP, Rodriquez-Lopez C, Blazquez A et al. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand. 1991;83:250-253.
23. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001;161: 2685-2692